Special Considerations for Lipid-Lowering Therapy in Women Reflecting Recent Randomized Trials

Area of Science:

• Cardiology
• Women's Health
• Pharmacology

Background:

• Atherosclerotic cardiovascular disease (ASCVD) is the primary cause of death for women in the USA.
• Women are historically underrepresented in clinical trials for cardiovascular disease.
• Despite evidence, women receive guideline-recommended lipid-lowering therapy less often and at lower intensities than men.

Purpose of the Study:

• To review lipid-lowering therapies for atherosclerotic cardiovascular disease (ASCVD) in women.
• To focus on special considerations for lipid management in women based on recent clinical trial data.
• To address the underutilization of guideline-recommended lipid-lowering therapy in eligible women.

Main Methods:

• Review of recent randomized clinical trials and studies.
• Analysis of lipid-lowering therapy efficacy and safety in women compared to men.
• Examination of expanded indications for lipid-lowering therapies.

Main Results:

• Recent trials confirm women benefit equally from lipid-lowering therapy as men.
• Evidence supports expanded uses for lipid-lowering agents beyond primary indications.
• Disparities persist in guideline-recommended therapy prescription and intensity for women.

Conclusions:

• Lipid-lowering therapies are crucial for reducing cardiovascular events in women.
• Addressing underrepresentation and treatment gaps in women is essential for equitable ASCVD care.
• Recent evidence supports broader application and tailored approaches to lipid management in women.